The JAK/STAT signaling cascade in gastric carcinoma (Review).

作者: PUJA KHANNA , PEI JOU CHUA , BOON HUAT BAY , GYEONG HUN BAEG

DOI: 10.3892/IJO.2015.3160

关键词:

摘要: Gastric carcinoma remains one of the most prevalent forms cancer worldwide, despite decline in incidence rates, increased awareness disease and advancement treatment strategies. Helicobacter pylori infection, dietary factors, lifestyle influences various genetic aberrations have been shown to contribute development progression gastric cancer. Recent studies on genomic landscape adenocarcinoma identified several key signaling molecules, including epidermal growth factor receptor family (ErbB) members, vascular endothelial (VEGFR) members PI3K/Akt/mTOR pathway components, that implicated molecular pathogenesis cancers. However, clinical trials with compounds target these molecules failed show a significant improvement overall survival rates when supplemented conventional therapies. Therefore, it is essential identify effective prognostic and/or diagnostic biomarkers develop targeted The JAK/STAT cascade principal signal transduction cytokine signaling, regulating cellular processes such as cell proliferation, differentiation, migration survival. Numerous vivo vitro dysregulated driving force solid cancers well hematopoietic malignancies. Hence, large number preclinical drugs targeting this are currently underway. Notably, aberrant has also In review, we focus ongoing research discuss therapeutic potential for

参考文章(126)
Weida Gong, Liwei Wang, James C. Yao, Jaffer A. Ajani, Daoyan Wei, Kenneth D. Aldape, Keping Xie, Raymond Sawaya, Suyun Huang, Expression of activated signal transducer and activator of transcription 3 predicts expression of vascular endothelial growth factor in and angiogenic phenotype of human gastric cancer. Clinical Cancer Research. ,vol. 11, pp. 1386- 1393 ,(2005) , 10.1158/1078-0432.CCR-04-0487
Katsutoshi Ando, Fumiyuki Takahashi, Shinji Motojima, Kei Nakashima, Norihiro Kaneko, Kazuei Hoshi, Kazuhisa Takahashi, Possible Role for Tocilizumab, an Anti–Interleukin-6 Receptor Antibody, in Treating Cancer Cachexia Journal of Clinical Oncology. ,vol. 31, pp. 69- 72 ,(2013) , 10.1200/JCO.2012.44.2020
Andrew S Giraud, Trevelyan R Menheniott, Louise M Judd, Targeting STAT3 in gastric cancer. Expert Opinion on Therapeutic Targets. ,vol. 16, pp. 889- 901 ,(2012) , 10.1517/14728222.2012.709238
Tom Waddell, Ian Chau, David Cunningham, David Gonzalez, Alicia Frances Clare Okines, Andrew Wotherspoon, Claire Saffery, Gary Middleton, Jonathan Wadsley, David Ferry, Wasat Mansoor, Tom Crosby, Fareeda Coxon, David Smith, Justin Waters, Timothy Iveson, Stephen Falk, Sarah Slater, Clare Peckitt, Yolanda Barbachano, Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial Lancet Oncology. ,vol. 14, pp. 481- 489 ,(2013) , 10.1016/S1470-2045(13)70096-2
C. Gravalos, A. Jimeno, HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target Annals of Oncology. ,vol. 19, pp. 1523- 1529 ,(2008) , 10.1093/ANNONC/MDN169
John Mascarenhas, Ronald Hoffman, Ruxolitinib: The First FDA Approved Therapy for the Treatment of Myelofibrosis: Figure 1. Clinical Cancer Research. ,vol. 18, pp. 3008- 3014 ,(2012) , 10.1158/1078-0432.CCR-11-3145
Daoyan Wei, Xiangdong Le, Leizhen Zheng, Liwei Wang, Jennifer A Frey, Allen C Gao, Zhihai Peng, Suyun Huang, Henry Q Xiong, James L Abbruzzese, Keping Xie, Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis Oncogene. ,vol. 22, pp. 319- 329 ,(2003) , 10.1038/SJ.ONC.1206122
Jing Shi, Demao Yao, Wei Liu, Na Wang, Hongjun Lv, Guanjun Zhang, Meiju Ji, Li Xu, Nongyue He, Bingyin Shi, Peng Hou, Highly frequent PIK3CA amplification is associated with poor prognosis in gastric cancer BMC Cancer. ,vol. 12, pp. 50- 50 ,(2012) , 10.1186/1471-2407-12-50
D. A. Harrison, The Jak/STAT pathway. Cold Spring Harbor Perspectives in Biology. ,vol. 4, pp. 1- ,(2012) , 10.1101/CSHPERSPECT.A011205
G Nardone, D Compare, A Rocco, Risk factors in gastric cancer. European Review for Medical and Pharmacological Sciences. ,vol. 14, pp. 302- 308 ,(2010)